Targeting of Hsp32 in Solid Tumors and Leukemias: A Novel Approach to Optimize Anticancer Therapy (Supplementry Material)

Title: Targeting of Hsp32 in Solid Tumors and Leukemias: A Novel Approach to Optimize Anticancer Therapy (Supplementry Material)

Volume: 9 Issue: 5

Author(s): A. K. Iyer, P. Valent, C. Zielinski, H. Maeda, C. Sillaber, R. Panzer-Grumayer, B. Marian, W. F. Pickl, M.-T. Krauth, K. V. Gleixner, H. Herrmann, E. Hadzijusufovic, E. Lackner, S. Cerny-Reiterer, G. Hormann, A. Gruze, A. Vales and M. Mayerhofer

Affiliation:

Keywords: Solid tumors, Leukemias, HO-1, Hsp32, SMA-ZnPP, targeted drugs

Abstract: Heat shock protein 32 (Hsp32), also known as heme oxygenase-1 (HO-1), is a stress-related anti-apoptotic molecule, that has been implicated in enhanced survival of neoplastic cells and in drug-resistance. We here show that Hsp32 is expressed in most solid tumors and hematopoietic neoplasms and may be employed as a new therapeutic target as evidenced by experiments using specific siRNA and a Hsp32-targeting pharmacologic inhibitor. This Hsp-32 targeting drug, SMA-ZnPP, was found to inhibit the proliferation of neoplastic cells with IC50 values ranging between 1 and 50 μM. In addition, SMA-ZnPP induced apoptosis in all neoplastic cells examined. Furthermore, SMA-ZnPP was found to synergize with other targeted and conventional drugs in producing growth-inhibition. Resulting synergistic effects were observed in all tumor- and leukemia cells examined. Interestingly, several of the drug partners, when applied as single agents, induced the expression of Hsp32 in neoplastic cells, suggesting that synergistic effects resulted from SMA-ZnPPinduced ablation of a Hsp32-mediated survival-pathway that is otherwise used by tumor cells to escape drug induced apoptosis. Together, Hsp32 is an important survival factor and target in solid tumors and hematopoietic neoplasms, and may be used to optimize anticancer therapy by combining conventional or targeted drugs with Hsp32-inhibitors. Based on these data, it seems desirable to explore the value of Hsp32-targeting drugs as anti-cancer agents in clinical trials.

Cite this article as:

Iyer K. A., Valent P., Zielinski C., Maeda H., Sillaber C., Panzer-Grumayer R., Marian B., Pickl F. W., Krauth M.-T., Gleixner V. K., Herrmann H., Hadzijusufovic E., Lackner E., Cerny-Reiterer S., Hormann G., Gruze A., Vales A. and Mayerhofer M., Targeting of Hsp32 in Solid Tumors and Leukemias: A Novel Approach to Optimize Anticancer Therapy (Supplementry Material), Current Cancer Drug Targets 2009; 9 (5) . https://dx.doi.org/10.2174/156800909789057024